The neuropeptide Substance P activates the cancer-promoting receptors HER2 and EGFR in breast cancer cells through two distinct molecular pathways — c-Src kinase and metalloproteinases — with dual blockade nearly eliminating this activation.
Near-complete abolition of HER2/EGFR activationAchieved by simultaneously blocking both c-Src and metalloproteinase pathways through which Substance P transactivates these cancer receptors
What the researchers found
The neuropeptide Substance P activates the cancer-driving receptors HER2 and EGFR in breast cancer cells through two pathways requiring c-Src kinase and metalloproteinases (MMPs). Inhibiting c-Src alone prevented Substance P-induced HER2 activation, while MMP inhibition reduced phosphorylation of both HER2 and EGFR. Dual inhibition of both c-Src and MMPs nearly abolished HER2 and EGFR activation and also reduced breast cancer cell viability and migration. These findings reveal that Substance P's tumor-promoting effects in breast cancer depend on both ligand-independent (c-Src) and ligand-dependent (MMP) signaling pathways.
Why it matters
HER2 and EGFR are major targets in breast cancer treatment, but drug resistance remains a significant clinical challenge. This study reveals that the neuropeptide Substance P can activate these receptors through an alternative route — the NK-1 receptor — bypassing the pathways that current targeted therapies block. Understanding this cross-talk mechanism could inform new combination treatment strategies to overcome drug resistance in HER2+ and EGFR+ breast cancers.
The numbers in context
4 breast cancer cell lines tested · Dual c-Src + MMP inhibition nearly abolished HER2/EGFR activation · NK-1R overexpression modulated c-Src activation
How the study worked
In vitro cell biology study using four breast cancer cell lines (MDA-MB-231, SK-BR-3, BT-474, MDA-MB-468). NK-1 receptor was overexpressed in one line and chemically inhibited in others. The roles of c-Src and metalloproteinases in Substance P-mediated HER2/EGFR activation were tested using specific inhibitors (c-Src inhibitor and MMP inhibitor 1,10-phenanthroline monohydrate). Cell viability and migration were assessed under single and dual inhibition conditions.
Who was studied
In vitro study using four human breast cancer cell lines (MDA-MB-231, SK-BR-3, BT-474, MDA-MB-468)
What this study cannot tell us
This is an in vitro study using cultured breast cancer cell lines, which may not fully represent the complexity of tumors in patients. The interactions between Substance P, the tumor microenvironment, and the immune system were not captured. No animal models or patient samples were used to validate the findings in a more physiological context.
How to read the evidence
This is a preclinical laboratory study using breast cancer cell lines. While the mechanistic findings are clearly demonstrated across multiple cell lines, they have not been validated in animal models or human patients.
When this study was published
Published in 2015, this study provided important mechanistic insights into neuropeptide-cancer receptor cross-talk. The NK-1 receptor and Substance P signaling in cancer remain active areas of research.
The bigger picture
The tumor microenvironment contains many signaling molecules, including neuropeptides like Substance P, that can influence cancer behavior in ways not targeted by standard therapies. This research highlights how a neuropeptide can bypass the pathways that current drugs block, potentially contributing to treatment resistance. The growing recognition of neuropeptide signaling in cancer biology is opening new avenues for combination therapies that target these alternative activation routes.
Questions still open
- Could NK-1 receptor antagonists (which block Substance P signaling) be combined with HER2-targeted therapies like trastuzumab to improve treatment outcomes?
- Do elevated Substance P levels in breast tumors correlate with worse clinical outcomes or resistance to HER2/EGFR-targeted drugs?
- Is this Substance P-mediated transactivation mechanism relevant in other cancer types that overexpress HER2 or EGFR?
Common questions
What is Substance P and what does it normally do in the body?
Could blocking Substance P help treat breast cancer?
Read the original research
The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.
PloS one, 10(6), e0129661
Citation
Garcia-Recio, Susana; Pastor-Arroyo, Eva M; Marín-Aguilera, Mercedes; Almendro, Vanessa; Gascón, Pedro. (2015). The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.. PloS one, 10(6), e0129661. https://doi.org/10.1371/journal.pone.0129661